Superworth

Travere Therapeutics price to free cash flow TVTX

Market value divided by free cash flow over the last twelve months, since 2016.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
163×
Apr 2018
Peer median
33.0×

Travere Therapeutics' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Apr 2018, at 163×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2018163×136×166×
2017299×280×308×
2016278×168×318×

Against its peers

Companies in Drug Manufacturers - General nearest Travere Therapeutics' size, closest first, today.

CompanyPrice to free cash flow
TVTXTravere Therapeuticsn/m
INDVIndivior Pharmaceuticalsn/m
ARQTArcutis Biotherapeutics100×
LQDALiquidia25.3×
KNSAKiniksa Pharmaceuticals International32.7×
LGNDLigand Pharmaceuticals46.0×
OGNOrganon6.4×
AMRXAmneal Pharmaceuticals50.9×
ALKSAlkermes plc.33.0×
NRIXNurix Therapeutics7.5×
TGTXTG Therapeutics477×
Peer median33.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Travere Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.